| Domain | Summary |
|---|---|
| Disease name | Neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities; a rare Mendelian syndrome linked primarily to biallelic **PTRHD1** variation (established) (pqac-00000000, pqac-00000001) |
| MONDO ID | **MONDO:0958323** (established disease identifier from Open Targets disease mapping) (pqac-00000000) |
| Causal gene | **PTRHD1** (*peptidyl-tRNA hydrolase domain containing 1*; OMIM gene noted in review as MIM *617342*) is the principal associated gene; **CENPO** also appears in disease-target association resources but with weaker/overlapping evidence and should be treated cautiously for disease causality here (pqac-00000000, pqac-00000001) |
| Inheritance | **Autosomal recessive / biallelic** inheritance; reported affected individuals were from consanguineous or likely recessive families (established) (pqac-00000001, pqac-00000002) |
| Known human evidence / families | Very limited human evidence: initially **3 families** reported in the literature — **2 unrelated consanguineous Iranian families** and **1 sub-Saharan African kindred** — with a later **2024 single case** carrying homozygous **p.Arg122Gln** and juvenile parkinsonism with ID/epilepsy (established for scarcity; exact total case count remains small) (pqac-00000000, pqac-00000001, pqac-00000002) |
| Typical temporal course | **Childhood neurodevelopmental impairment** (global developmental delay/intellectual disability ± behavioral abnormalities) followed by **juvenile/early-adult parkinsonism**, usually in the **20–30 year** range in the earlier reports; progression appears chronic/progressive but detailed natural-history staging is not available (partly established, partly inferred) (pqac-00000001, pqac-00000002) |
| Core phenotypes with suggested HPO terms | Intellectual disability **HP:0001249**; global developmental delay **HP:0001263**; behavioral abnormality **HP:0000708**; parkinsonism **HP:0001300**; bradykinesia **HP:0002067**; rigidity **HP:0002063**; tremor/postural tremor **HP:0001337**; pyramidal signs/spasticity **HP:0002493 / HP:0001257**; peripheral neuropathy **HP:0009830**; hypersomnia **HP:0001262**; generalized seizures/epilepsy reported in at least one later case **HP:0002197 / HP:0001250** (phenotype set combines established reported findings with ontology suggestions) (pqac-00000001, pqac-00000002) |
| Variant classes | Reported disease-associated variants include **homozygous missense** variants and a **28-nt frameshift deletion**; later literature adds **homozygous p.Arg122Gln** in an individual with ID, generalized epilepsy, and juvenile parkinsonism (established at class level; exhaustive variant list not recoverable from currently available context) (pqac-00000000, pqac-00000001, pqac-00000002) |
| Mechanism confidence | **Low-to-moderate confidence mechanism.** Reviews propose **loss of function** of PTRHD1 and possible involvement in **ubiquitin-proteasome / protein quality control** biology, but direct disease-specific mechanistic validation remains sparse; no robust pathway model is established (conservative interpretation) (pqac-00000001, pqac-00000002) |
| Diagnosis | Diagnosis is currently **genomic**: suspected from the syndromic combination of developmental disorder/behavioral abnormalities plus juvenile or early-onset parkinsonism, then confirmed by **WES/WGS or targeted gene panel** showing biallelic PTRHD1 variants. No disease-specific biomarker, clinical criteria, or pathognomonic laboratory test was identified (established scarcity; testing approach partly inferred from rare-disease practice) (pqac-00000001, pqac-00000002) |
| Treatment | **No disease-specific therapy established.** Management is **supportive/symptomatic**, extrapolated from juvenile parkinsonism and neurodevelopmental care. Published disease-specific quantitative data on levodopa response, DBS, rehabilitation outcomes, or genotype-guided treatment were not identified in the available evidence base (pqac-00000002) |
| Epidemiology | **Ultra-rare**; only a handful of families/cases reported. No reliable prevalence, incidence, carrier frequency, penetrance, sex ratio, or population-based estimates are available (established evidence gap) (pqac-00000001, pqac-00000002) |
| Trials | **No relevant disease-specific interventional clinical trials identified** for PTRHD1-related disease; no gene therapy, RNA therapy, or targeted experimental program was found in the searched trial resources (pqac-00000002) |
| Major evidence gaps | Missing or very limited data on: full variant spectrum; allele frequencies; penetrance/expressivity; MRI/DAT-SPECT patterns; longitudinal prognosis/survival; treatment response rates; QoL; environmental modifiers; protective factors; epigenetics; transcriptomics/proteomics/metabolomics; and validated animal/cellular disease models (pqac-00000001, pqac-00000002) |


*Table: This table provides a compact knowledge-base summary of PTRHD1-related neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities. It emphasizes established facts, flags inferred points conservatively, and highlights major evidence gaps for curation and future research.*